Parmar Kush's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Nov 5, 2021
- Accession no.
- 0001104659-21-134772
- Filed
- Nov 5, 2021
- Trade date
- Nov 2, 2021
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 5 derivative transactions. Open-market purchases total $5.00M. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Parmar KushCIK 0001664281 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 | Common Stock | CConversionAcquired | +318,616 | –F1 | – | 649,771 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionAcquired | +2,371,739 | –F1 | – | 3,021,510 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionAcquired | +564,217 | –F1 | – | 564,217 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionAcquired | +254,512 | –F1 | – | 3,276,022 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionAcquired | +318,140 | –F1 | – | 882,357 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | PPurchaseAcquired | +250,000 | $20.00 | +$5,000,000 | 1,132,357 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 | Common Stock | CConversionDisposed | −318,616 | $0.00F1 | $0 | 0 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionDisposed | −2,371,739 | $0.00F1 | $0 | 0 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionDisposed | −564,217 | $0.00F1 | $0 | 0 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionDisposed | −254,512 | $0.00F1 | $0 | 0 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionDisposed | −318,140 | $0.00F1 | $0 | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
Referenced by the price of 5 transactions in Table I and 5 transactions in Table II.